<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>IUIS classification of diseases of immune dysregulation (category IV inborn errors of immunity)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">IUIS classification of diseases of immune dysregulation (category IV inborn errors of immunity)</h1>
<div class="graphic"><div class="figure"><div class="ttl">IUIS classification of diseases of immune dysregulation (category IV inborn errors of immunity)</div><div class="cntnt"><table cellspacing="0"><colgroup span="8" width="12.5%"></colgroup> <tbody> <tr> <td class="subtitle1">Disease</td> <td class="subtitle1">Genetic defect</td> <td class="subtitle1">Inheritance</td> <td class="subtitle1">OMIM</td> <td class="subtitle1">Circulating T cells</td> <td class="subtitle1">Circulating B cells</td> <td class="subtitle1">Functional defect</td> <td class="subtitle1">Associated features</td> </tr> <tr> <td class="subtitle2_left" colspan="8">Familial hemophagocytic lymphohistiocytosis (FHL syndromes)</td> </tr> <tr> <td class="indent1">Perforin deficiency (FHL2)</td> <td>Perforin 1 (<em>PRF1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/170280" target="_blank">170280</a></td> <td>Increased activated T cells</td> <td>Normal</td> <td>Decreased to absent NK and CTL activities; cytotoxicity</td> <td>Fever, HSM, HLH, cytopenias</td> </tr> <tr> <td class="indent1">UNC13D/Munc13-4 deficiency (FHL3)</td> <td>Unc-13 homolog D (<em>UNC13D</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/608897" target="_blank">608897</a></td> <td>Increased activated T cells</td> <td>Normal</td> <td>Decreased to absent NK and CTL activities (cytotoxicity and/or degranulation)</td> <td>Fever, HSM, HLH, cytopenias</td> </tr> <tr> <td class="indent1">Syntaxin 11 deficiency (FHL4)</td> <td>Syntaxin 11 (<em>STX11</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/605014" target="_blank">605014</a></td> <td>Increased activated T cells</td> <td>Normal</td> <td>Decreased to absent NK and CTL activities (cytotoxicity and/or degranulation)</td> <td>Fever, HSM, HLH, cytopenias</td> </tr> <tr> <td class="indent1">STXBP/Munc18-2 deficiency (FHL5)</td> <td>Syntaxin binding protein 2 (<em>STXBP2</em>)</td> <td>AR or AD</td> <td><a href="https://www.omim.org/entry/601717" target="_blank">601717</a></td> <td>Increased activated T cells</td> <td>Normal</td> <td>Decreased to absent NK and CTL activities (cytotoxicity and/or degranulation)</td> <td>Fever, HSM, HLH, cytopenias</td> </tr> <tr> <td class="indent1">FAAP24 deficiency</td> <td>FA core complex-associated protein 24 (<em>FAAP24</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/610884" target="_blank">610884</a></td> <td>Increased activated T cells</td> <td>Normal</td> <td>Failure to kill autologous EBV transformed B cells; normal NK cell function</td> <td>EBV-driven lymphoproliferative disease</td> </tr> <tr> <td class="indent1">SLC7A7 deficiency</td> <td>Solute carrier family 7 member 7 (<em>SLC7A7</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/222700" target="_blank">222700</a></td> <td>Normal</td> <td>Normal</td> <td>Hyperinflammatory response to macrophages; normal NK cell function</td> <td>Lysinuric protein intolerance, bleeding tendency, alveolar proteinosis</td> </tr> <tr> <td class="indent1">RHOG deficiency</td> <td>Ras homolog family member G (<em>RHOG</em>)</td> <td>AR</td> <td>Â </td> <td>Normal</td> <td>Slightly reduced</td> <td>Impaired CTL and NK cell cytotoxicity</td> <td>HLH, hemophagocytosis, HSM, fever, cytopenias, low hemoglobin, hypertriglyceridemia, elevated ferritin, sCD25</td> </tr> <tr> <td class="subtitle2_left" colspan="8">FHL syndromes with hypopigmentation</td> </tr> <tr> <td class="indent1">Chediak-Higashi syndrome</td> <td>Lysosomal trafficking regulator (<em>LYST</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/606897" target="_blank">606897</a></td> <td>Increased activated T cells</td> <td>Normal</td> <td>Decreased NK and CTL activities (cytotoxicity and/or degranulation)</td> <td>Partial albinism, recurrent infections, fever, HSM, HLH, giant lysosomes, neutropenia, cytopenias, bleeding tendency, progressive neurologic dysfunction</td> </tr> <tr> <td class="indent1">Griscelli syndrome, type 2</td> <td>RAB27A, member RAS oncogene family (<em>RAB27A</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/603868" target="_blank">603868</a></td> <td>Normal</td> <td>Normal</td> <td>Decreased NK and CTL activities (cytotoxicity and/or degranulation)</td> <td>Partial albinism, fever, HSM, HLH, cytopenias</td> </tr> <tr> <td class="indent1">Hermansky-Pudlak syndrome, type 2</td> <td>Adaptor-related protein complex 3 subunit beta 1 (<em>AP3B1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/603401" target="_blank">603401</a></td> <td>Normal</td> <td>Normal</td> <td>Decreased NK and CTL activities (cytotoxicity and/or degranulation)</td> <td>Partial albinism, recurrent infections, pulmonary fibrosis, increased bleeding, neutropenia, HLH</td> </tr> <tr> <td class="indent1">Hermansky-Pudlak syndrome, type 10</td> <td>Adaptor-related protein complex 3 subunit delta 1 (<em>AP3D1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/617050" target="_blank">617050</a></td> <td>Normal</td> <td>Normal</td> <td>Decreased NK and CTL activities (cytotoxicity and/or degranulation)</td> <td>Oculocutaneous albinism, severe neutropenia, recurrent infections, seizures, hearing loss, neurodevelopmental delay</td> </tr> <tr> <td class="indent1">CEBPE neofunction</td> <td>CCAAT enhancer binding protein epsilon (<em>CEBPE</em>)</td> <td>AR GOF</td> <td><a href="https://www.omim.org/entry/245480" target="_blank">245480</a></td> <td>Mild reduction</td> <td>Not one</td> <td>Autoinflammatory activation/increased IFN gene expression; altered chromatin occupancy of mutant CEBPE; transcriptional changes</td> <td>Recurrent abdominal pain, aseptic fever, systemic inflammation, abscesses, ulceration, infections, mild bleeding diathesis</td> </tr> <tr> <td class="subtitle2_left" colspan="8">Regulatory T cell defects</td> </tr> <tr> <td class="indent1">Immune dysregulation, polyendocrinopathy, enteropathy X linked (IPEX)</td> <td>Forkhead box P3 (<em>FOXP3</em>)</td> <td>XL</td> <td><a href="https://www.omim.org/entry/300292" target="_blank">300292</a></td> <td>Normal</td> <td>Normal</td> <td>Lack of and/or impaired function of CD4<sup>+</sup> CD25<sup>+</sup> FOXP3<sup>+</sup> Tregs</td> <td>Autoimmune enteropathy, early-onset diabetes, thyroiditis, hemolytic anemia, thrombocytopenia, eczema, elevated IgE and IgA</td> </tr> <tr> <td class="indent1">CD25 deficiency</td> <td>IL-2 receptor subunit alpha (<em>IL2RA</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/147730" target="_blank">147730</a></td> <td>Normal to decreased</td> <td>Normal</td> <td>No CD4<sup>+</sup> CD25<sup>+</sup> cells with impaired function of Tregs</td> <td>Lymphoproliferation, autoimmunity, impaired T cell proliferation in vitro</td> </tr> <tr> <td class="indent1">C122 deficiency</td> <td>IL-2 receptor subunit beta (<em>IL2RB</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/618495" target="_blank">618495</a></td> <td>Increased memory CD8 T cells; decreased Tregs</td> <td>Increased memory B cells</td> <td>Diminished IL2R-beta expression; dysregulated signaling in response to IL-2/IL-15; increased immature NK cells</td> <td>Lymphoproliferation, lymphadenopathy, HSM, AIHA, dermatitis, enteropathy, hypergammaglobulinemia, recurrent viral infections (EBV, CMV)</td> </tr> <tr> <td class="indent1">CTLA4 haploinsufficiency (ALPS-V)</td> <td>Cytotoxic T lymphocyte-associated protein 4 (<em>CTLA4</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/123890" target="_blank">123890</a></td> <td>Decreased</td> <td>Decreased</td> <td>Impaired function of Tregs</td> <td>Autoimmune cytopenias, enteropathy, interstitial lung disease, extra-lymphoid lymphocytic infiltration, recurrent infections</td> </tr> <tr> <td class="indent1">LRBA deficiency</td> <td>LPS-responsive beige-like anchor protein (<em>LRBA</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/606453" target="_blank">606453</a></td> <td>Normal or decreased CD4 numbers; T cell dysregulation</td> <td>Low or normal numbers of B cells</td> <td>Reduced IgG and IgA in most</td> <td>Recurrent infections, IBD, autoimmunity</td> </tr> <tr> <td class="indent1">DEF6 deficiency</td> <td>DEF6 guanine nucleotide exchange factor (<em>DEF6</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/610094" target="_blank">610094</a></td> <td>Mild CD4 and CD8 lymphopenia</td> <td>Low or normal numbers of B cells</td> <td>Impaired Treg function</td> <td>Enteropathy, HSM, cardiomyopathy, recurrent infections</td> </tr> <tr> <td class="indent1">STAT3 GOF mutation</td> <td>Signal transducer and activator of transcription 3 (<em>STAT3</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/102582" target="_blank">102582</a></td> <td>Decreased</td> <td>Decreased</td> <td>Enhanced STAT3 signaling leading to increased Th17 cell differentiation, lymphoproliferation, and autoimmunity; decreased Tregs and impaired function</td> <td>Lymphoproliferation, solid organ autoimmunity, recurrent infections</td> </tr> <tr> <td class="indent1">BACH2 deficiency</td> <td>BTB domain and CNC homolog 2 (<em>BACH2</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/605394" target="_blank">605394</a></td> <td>Progressive T cell lymphopenia</td> <td>Impaired memory B cell development</td> <td>Haploinsufficiency for a critical lineage specification transcription factor</td> <td>Lymphocytic colitis, sinopulmonary infections</td> </tr> <tr> <td class="indent1">FERMT1 deficiency</td> <td>FERM domain-containing kindlin 1 (<em>FERMT1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/173650" target="_blank">173650</a></td> <td>Normal</td> <td>Normal</td> <td>Intracellular accumulation of IgG, IgM, IgA, and C3 in colloid bodies under the basement membrane</td> <td>Dermatosis characterized by congenital blistering, skin atrophy, photosensitivity, skin fragility, and scaling</td> </tr> <tr> <td class="indent1">IKAROS GOF</td> <td>IKAROS family zinc finger 1 (<em>IKZF1</em>)</td> <td>AD GOF</td> <td>Â </td> <td>Normal</td> <td>Normal/mild decrease</td> <td>Increased binding of mutant IKAROS to DNA/target genes</td> <td>Multiple autoimmune features (diabetes, colitis, thyroiditis), allergy, lymphoproliferation, plasma cell expansion (IgG4+), Evans syndrome, recurrent infections</td> </tr> <tr> <td class="subtitle2_left" colspan="8">Autoimmunity with or without lymphoproliferation</td> </tr> <tr> <td class="indent1">Autoimmune polyendocrinopathy with candidiasis and ectodermal dystrophy (APECED; APS-1)</td> <td>Autoimmune regulator (<em>AIRE</em>)</td> <td>AR or AD</td> <td><a href="https://www.omim.org/entry/240300" target="_blank">240300</a></td> <td>Normal</td> <td>Normal</td> <td>AIRE serves as the checkpoint in the thymus for negative selection of autoreactive T cells and for generation of Tregs</td> <td>Autoimmunity, hypoparathyroidism, hypothyroidism, adrenal insufficiency, diabetes, gonadal dysfunction and other endocrine abnormalities, dental enamel hypoplasia, alopecia areata, enteropathy, pernicious anemia, chronic mucocutaneous candidiasis</td> </tr> <tr> <td class="indent1">ITCH deficiency</td> <td>Itchy E3 ubiquitin protein ligase (<em>ITCH</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/606409" target="_blank">606409</a></td> <td>Not assessed</td> <td>Not assessed</td> <td>May cause immune dysregulation by affecting both anergy induction in autoreactive effector T cells and generation of Tregs</td> <td>Early-onset chronic lung disease (interstitial pneumonitis), autoimmunity (thyroiditis, type I diabetes, chronic diarrhea/enteropathy, and hepatitis), failure to thrive, developmental delay, dysmorphic facial features</td> </tr> <tr> <td class="indent1">Tripeptidyl-peptidase II deficiency</td> <td>Tripeptidyl peptidase 2 (<em>TPP2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/190470" target="_blank">190470</a></td> <td>Decreased</td> <td>Decreased</td> <td>Premature immunosenescence and immune dysregulation</td> <td>Variable lymphoproliferation, severe autoimmune cytopenias, hypergammaglobulinemia, recurrent infections</td> </tr> <tr> <td class="indent1">JAK1 GOF</td> <td>Janus kinase 1 <em>(JAK1</em>)</td> <td>AD GOF</td> <td><a href="https://www.omim.org/entry/147795" target="_blank">147795</a></td> <td>Not assessed</td> <td>Not assessed</td> <td>Hyperactive JAK1</td> <td>HSM, eosinophilia, eosinophilic enteritis, thyroid disease, poor growth, viral infections</td> </tr> <tr> <td class="indent1">Prolidase deficiency</td> <td>Peptidase D (<em>PEPD</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/613230" target="_blank">613230</a></td> <td>Normal</td> <td>Normal</td> <td>Peptidase D</td> <td>Autoantibodies common, chronic skin ulcers, eczema, infections</td> </tr> <tr> <td class="indent1">SOCS1 haploinsufficiency</td> <td>Suppressor of cytokine signaling 1 (<em>SOCS1</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/619375" target="_blank">619375</a></td> <td>Decreased</td> <td>Reduced switched memory B cells</td> <td>Increased pSTAT1; increased type I/II IFN signature</td> <td>Early-onset severe multisystemic autoimmunity, neutropenia, lymphopenia, ITP, AIHA, SLE, GN, HSM, psoriasis, arthritis, thyroiditis, hepatitis, recurrent bacterial infections, incomplete penetrance</td> </tr> <tr> <td class="indent1">PD-1 deficiency</td> <td>Programmed cell death 1 (<em>PDCD1</em>)</td> <td>AR</td> <td>Â </td> <td>Mostly intact</td> <td>Normal</td> <td>Lack of PD-1 on patient PBMCs; reduced IFN-gamma production in response to mycobacterial stimuli</td> <td>Tuberculosis, autoimmunity (type 1 diabetes, hypothyroidism, JIA), fatal pulmonary autoimmunity, HSM</td> </tr> <tr> <td class="subtitle2_left" colspan="8">Immune dysregulation with colitis</td> </tr> <tr> <td class="indent1">IL-10 deficiency</td> <td>Interleukin 10 (<em>IL10</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/124092" target="_blank">124092</a></td> <td>Normal</td> <td>Normal</td> <td>No functional IL-10 secretion</td> <td>IBD, folliculitis, recurrent respiratory diseases, arthritis</td> </tr> <tr> <td class="indent1" rowspan="2">IL-10R deficiency</td> <td>Interleukin 10 receptor subunit alpha (<em>IL10RA</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/146933" target="_blank">146933</a></td> <td>Normal</td> <td>Normal</td> <td>Leukocytes unresponsive to IL-10</td> <td>IBD, folliculitis, recurrent respiratory diseases, arthritis, lymphoma</td> </tr> <tr> <td>Interleukin 10 receptor subunit beta (<em>IL10RB</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/123889" target="_blank">123889</a></td> <td>Normal</td> <td>Normal</td> <td>Leukocytes unresponsive to IL-10, IL-22, IL-26, IL-28A, IL-28B, and IL-29</td> <td>IBD, folliculitis, recurrent respiratory diseases, arthritis, lymphoma</td> </tr> <tr> <td class="indent1">NFAT5 haploinsufficiency</td> <td>Nuclear factor of activated T cells 5 (<em>NFAT5</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/604708" target="_blank">604708</a></td> <td>Normal</td> <td>Normal</td> <td>Decreased memory B cells and plasmablasts</td> <td>IBD, recurrent sinopulmonary infections</td> </tr> <tr> <td class="indent1">TGFB1 deficiency</td> <td>Transforming growth factor beta 1 <em>(TGFB1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/618213" target="_blank">618213</a></td> <td>Normal</td> <td>Normal</td> <td>Decreased T cell proliferation in response to anti-CD3</td> <td>IBD, immunodeficiency, recurrent viral infections, microcephaly, encephalopathy</td> </tr> <tr> <td class="indent1">RIPK1</td> <td>Receptor interacting serine/threonine kinase 1 (<em>RIPK1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/618108" target="_blank">618108</a></td> <td>Reduced</td> <td>Normal/reduced</td> <td>Reduced activation of MAPK and NFkB pathways</td> <td>Recurrent infections, early-onset IBD, progressive polyarthritis</td> </tr> <tr> <td class="indent1">ELF4 deficiency</td> <td>E74-like ETS transcription factor 4 (<em>ELF4</em>)</td> <td>XL</td> <td><a href="https://www.omim.org/entry/301074" target="_blank">301074</a></td> <td>Normal</td> <td>Normal</td> <td>Hyperinflammatory macrophages</td> <td>Early-onset IBD/mucosal autoinflammation; fever; ulcers; responded to IL-1, TNF, or IIL-12p40 blockage</td> </tr> <tr> <td class="subtitle2_left" colspan="8">Autoimmune lymphoproliferative syndrome (ALPS; Canale-Smith syndrome)</td> </tr> <tr> <td class="indent1">ALPS-FAS</td> <td>TNF receptor superfamily member 6b <em>(TNFRSF6</em>)</td> <td>AR or AD</td> <td><a href="https://www.omim.org/entry/134637" target="_blank">134637</a></td> <td>Increased TCR <span class="nowrap_whitespace">alpha-beta<sup>+</sup></span> <span class="nowrap_whitespace">CD4<sup>â</sup>CD8<sup>â</sup></span> DN T cells</td> <td>Normal; low memory B cells</td> <td>Apoptosis defect Fas mediated</td> <td>Splenomegaly; adenopathies; autoimmune cytopenias; increased lymphoma risk; IgG and IgA normal or increased; elevated serum FasL, IL-10, and vitamin B12</td> </tr> <tr> <td class="indent1">ALPS-FASLG</td> <td>Fas ligand (<em>FASLG</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/134638" target="_blank">134638</a></td> <td>Increased DN T cells</td> <td>Normal</td> <td>Apoptosis defect FasL mediated</td> <td>Splenomegaly, adenopathies, autoimmune cytopenias, SLE, soluble FasL is not elevated</td> </tr> <tr> <td class="indent1">ALPS-caspase 10</td> <td>Caspase 10 (<em>CASP10</em>)</td> <td>AD</td> <td><a href="https://www.omim.org/entry/601762" target="_blank">601762</a></td> <td>Increased DN T cells</td> <td>Normal</td> <td>Defective lymphocyte apoptosis</td> <td>Adenopathies, splenomegaly, autoimmunity</td> </tr> <tr> <td class="indent1">ALPS-caspase 8</td> <td>Caspase 8 (<em>CASP8</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/601763" target="_blank">601763</a></td> <td>Slightly increased N T cells</td> <td>Normal</td> <td>Defective lymphocyte apoptosis and activation</td> <td>Adenopathies, splenomegaly, bacterial and viral infections, hypogammaglobulinemia</td> </tr> <tr> <td class="indent1">FADD deficiency</td> <td>Fas associated via death domain (<em>FADD</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/602457" target="_blank">602457</a></td> <td>Increased DN T cells</td> <td>Normal</td> <td>Defective lymphocyte apoptosis</td> <td>Functional hyposplenism, bacterial and viral infections, recurrent episodes of encephalopathy and liver dysfunction</td> </tr> <tr> <td class="subtitle2_left" colspan="8">Susceptibility to EBV and lymphoproliferative conditions</td> </tr> <tr> <td class="indent1">SAP deficiency (XLP1)</td> <td>SH2 domain-containing 1A (<em>SH2D1A</em>)</td> <td>XL</td> <td><a href="https://www.omim.org/entry/300490" target="_blank">300490</a></td> <td>Normal or increased activated T cells</td> <td>Reduced memory B cells</td> <td>Reduced NK cell and CTL cytotoxic activity</td> <td>Clinical and immunologic features triggered by EBV infection, HLH, lymphoproliferation, aplastic anemia, lymphoma, hypogammaglobulinemia, absent iNKT cells</td> </tr> <tr> <td class="indent1">XIAP deficiency (XLP2)</td> <td>X-linked inhibitor of apoptosis (<em>XIAP</em>)</td> <td>XL</td> <td><a href="https://www.omim.org/entry/300079" target="_blank">300079</a></td> <td>Normal or increased activated T cells; low/normal iNKT cells</td> <td>Normal or reduced memory B cells</td> <td>Increased T cells; susceptibility to apoptosis to CD95 and enhanced AICD</td> <td>EBV infection, splenomegaly, lymphoproliferation, HLH, colitis, IB, hepatitis, low iNKT cells</td> </tr> <tr> <td class="indent1">CD27 deficiency</td> <td>CD27 molecule (<em>CD27</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/615122" target="_blank">615122</a></td> <td>Normal</td> <td>No memory B cells</td> <td>Hypogammaglobulinemia, poor antibody responses to some vaccines/infections</td> <td>Features trigged by EBV infection, HLH, aplastic anemia, low iNKT cells, B lymphoma</td> </tr> <tr> <td class="indent1">CD70 deficiency</td> <td>CD70 molecule (<em>CD70</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/602840" target="_blank">602840</a></td> <td>Normal number; low Treg; poor activation and function</td> <td>Decreased memory B cells</td> <td>Hypogammaglobulinemia; poor antibody responses to some vaccines/infections</td> <td>EBV susceptibility, Hodgkin lymphoma, autoimmunity in some patients</td> </tr> <tr> <td class="indent1">CTPS1 deficiency</td> <td>CTP synthase 1 (<em>CTPS1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/615897" target="_blank">615897</a></td> <td>Normal to low, but reduced activation and proliferation</td> <td>Decreased memory B cells</td> <td>Normal/high IgG; poor proliferation to antigen</td> <td>Recurrent/chronic bacterial and viral infections (EBV, VZV), EBV lymphoproliferation, B cell non-Hodgkin lymphoma</td> </tr> <tr> <td class="indent1">CD137 deficiency (41BB)</td> <td>TNF receptor superfamily member 9 (<em>TNFRSF9</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/602250" target="_blank">602250</a></td> <td>Normal</td> <td>Normal</td> <td>Low IgG and IgA; poor responses to T cell-dependent and T cell-independent antigens; decreased T cell proliferation; IFN-gamma secretion; cytotoxicity</td> <td>EBV lymphoproliferation, B cell lymphoma, chronic active EBV infection</td> </tr> <tr> <td class="indent1">RASGRP1 deficiency</td> <td>RAS guanyl-releasing protein 1 (<em>RASGRP1</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/603962" target="_blank">603962</a></td> <td>Poor activation, proliferation, and motility; reduced naÃ¯ve T cells</td> <td>Poor activation, proliferation, and motility</td> <td>Normal IgM and IgG; increased IgA</td> <td>Recurrent pneumonia, herpesvirus infections, EBV-associated lymphoma, decreased NK cell function</td> </tr> <tr> <td class="indent1">RLTPR deficiency</td> <td>Capping protein regulator and myosin 1 linker 2 (<em>CARMIL2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/610859" target="_blank">610859</a></td> <td>Normal number; high CD4; increased naÃ¯ve CD4<sup>+</sup> and CD8<sup>+</sup>; low Treg and MAIT; poor CD28-induced function</td> <td>Normal B cell numbers; reduced memory B cells</td> <td>Normal to low; poor T-dependent antibody response</td> <td>Recurrent bacterial, fungal, and mycobacterial infections; viral warts; molluscum and EBV lymphoproliferative and other malignancy; atopy</td> </tr> <tr> <td class="indent1">X-linked magnesium EBV and neoplasia (XMEN)</td> <td>Magnesium transporter 1 (<em>MAGT1</em>)</td> <td>XL</td> <td><a href="https://www.omim.org/entry/300853" target="_blank">300853</a></td> <td>Low CD4; low recent thymic emigrant cells; inverted CD4/CD8 ratio; reduced MAIT cells; poor proliferation to CD3</td> <td>Normal but decreased memory B cells</td> <td>Progressive hypogammaglobulinemia; reduced NK cell and CTL cytotoxic activity due to impaired expression of NKG2D</td> <td>EBV infection, lymphoma, viral infections, respiratory and GI infections, glycosylation defects</td> </tr> <tr> <td class="indent1">PRKCD deficiency</td> <td>Protein kinase C delta (<em>PRKCD</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/615559" target="_blank">615559</a></td> <td>Normal</td> <td>Low memory B cells; high CD5 B cells</td> <td>Apoptotic defects in B cells</td> <td>Recurrent infections, EBV chronic infection, lymphoproliferation, SLE-like autoimmunity (nephrotic and antiphospholipid syndromes), low IgG</td> </tr> <tr> <td class="indent1">TET2 deficiency</td> <td>Tet methylcytosine dioxygenase 2 (<em>TET2</em>)</td> <td>AR</td> <td><a href="https://www.omim.org/entry/619126" target="_blank">619126</a></td> <td>Increased <span class="nowrap_whitespace">CD4<sup>â</sup>CD8<sup>â</sup></span> T cells</td> <td>Low memory B cells</td> <td>DNA hypermethylation; defective Fas-mediated apoptosis</td> <td>ALPS-like, recurrent viral infections, EBV viremia, lymphadenopathy, HSM, autoimmunity, B lymphoma, failure to thrive, developmental delay</td> </tr> </tbody></table></div><div class="graphic_lgnd">Total number of mutant genes in table: 52.</div><div class="graphic_footnotes">IUIS: International Union of Immunological Societies; 
    AR: autosomal recessive; 
    NK: natural killer; 
    CTL: cytotoxic T lymphocyte;
    HSM: hepatosplenomegaly; 
    HLH: hemophagocytic lymphohistiocytosis; 
    AD: autosomal dominant; 
    EBV: Epstein-Barr virus; 
    GOF: gain of function; 
    IFN: interferon; 
    XL: X linked; 
    CD: cluster of differentiation; 
    Treg: regulatory T cell; 
    IgE: immunoglobulin E; 
    IgA: immunoglobulin A; 
    IL: interleukin; 
    AIHA: autoimmune hemolytic anemia; 
    CMV: cytomegalovirus; 
    ALPS: autoimmune lymphoproliferative syndrome; 
    IgG: immunoglobulin G; 
    IBD: inflammatory bowel disease; 
    Th17: T helper type 17; 
    IgM: immunoglobulin M; 
    DNA: deoxyribonucleic acid; 
    APS-1: autoimmune polyglandular syndrome type 1; 
    pSTAT: phosphorylated signal transducer and activator of transcription; 
    ITP: immune thrombocytopenia; 
    SLE: systemic lupus erythematosus; 
    GN; glomerulonephritis; 
    PBMC: peripheral blood mononuclear cell; 
    JIA: juvenile idiopathic arthritis; 
    MAPK: mitogen-activated protein kinase; 
    NFkB: nuclear factor kappa B; 
    TNF: tumor necrosis factor; 
    Fas: Fas cell surface death receptor; 
    TCR: T cell receptor; 
    DN: double negative; 
    FasL: Fas ligand; 
    SAP: SLAM-associated protein; 
    XLP: X-linked lymphoproliferative disease; 
    iNKT: invariant natural killer T; 
    AICD: activation-induced cell death; 
    VZV: varicella-zoster virus; 
    RLTPR: RGD motif, leucine rich repeats, tropomodulin domain and proline-rich containing; 
    MAIT: mucosal-associated invariant T; 
    NKG2D: natural killer group 2D; 
    GI: gastrointestinal.</div><div class="graphic_reference">From: Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2022; 42:1473. Copyright Â© 2022 The Authors. Reproduced under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License 4.0</a>.</div><div id="graphicVersion">Graphic 139954 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
